![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Sommerhäuser, G.; Kurreck, A.; Stintzing, S.; Heinemann, V.; Fischer von Weikersthal, L.; Dechow, T.; Kaiser, F.; Karthaus, M.; Schwaner, I.; Fuchs, M.; König, A.; Roderburg, C.; Hoyer, I.; Quante, M.; Kiani, A.; Fruehauf, S.; Müller, L.; Reinacher-Schick, A.; Ettrich, T. J.; Stahler, A. und Modest, D. P.
(2022):
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
In: BMC Cancer, Bd. 22, Nr. 1, 820
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Stahler, A.; Stintzing, S.; Urbischek, M.; Modest, D. P.; Fischer von Weikersthal, L.; Kumbrink, J.; Heinemann, V.; Kirchner, T. und Jung, A.
(2016):
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
In: Annals of Oncology, Bd. 27
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746